TuBerculosis Vaccine Initiative   Report issue

Academic/Hospital Phase 3
Founded: Lelystad Netherlands (2008)

Organization Overview

First Clinical Trial
2013
NCT02013245
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

TuBerculosis Vaccine Initiative

Active Ingredients

Drugs in Phase 3 Trials (2)

bacille calmette-guerin (2 trials)

mtbvac (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Latent Tuberculosis (Phase 2)

Tuberculosis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 2